| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_336b63f79c2ddba567f69f4962c8a437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb1d966b0cdbe31c5766df6c9a757d12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ad18bec0f022d014fe381db8811ed01f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2008-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bec45b0cc776cf47d876454ee7fd5e88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6bafcfbfa44d0d599714405e7c0f8f0 |
| publicationDate |
2008-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008107909-A1 |
| titleOfInvention |
Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and a process thereof |
| abstract |
The present invention relates to a pharmaceutical composition having dopaminergic activity and other related pharmaceutical activities comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s); a process of preparing a pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s), wherein the process comprising steps of: (a) extracting a clear solution containing trigonelline and 4-hydroxyisoleucine from plant source; and (b) optionally precipitating derivative(s) of trigonelline and 4-hydroxyisoleucine from the clear solution and obtaining said composition; and an in-vitro method to increase levels of dopamine or to inhibit prolactin by allowing composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s) to bind to cell receptors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10493088-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9795676-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108697686-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108697686-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101810698-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017046777-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2016322956-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012529469-A |
| priorityDate |
2007-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |